Novartis Stock Price, News & Analysis (NYSE:NVS)

$85.33 +0.13 (+0.15 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$85.33
Today's Range$84.45 - $85.38
52-Week Range$72.67 - $94.19
Volume1.13 million shs
Average Volume1.79 million shs
Market Capitalization$223.28 billion
P/E Ratio26.02
Dividend Yield3.05%
Beta0.74

About Novartis (NYSE:NVS)

Novartis logoNovartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

Receive NVS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNYSE:NVS
CUSIPN/A
Phone+41-61-3241111

Debt

Debt-to-Equity Ratio0.31%
Current Ratio1.21%
Quick Ratio0.91%

Price-To-Earnings

Trailing P/E Ratio26.015243902439
Forward P/E Ratio15.92
P/E Growth1.97

Sales & Book Value

Annual Sales$49.11 billion
Price / Sales4.03
Cash Flow$7.69 per share
Price / Cash11.10
Book Value$32.03 per share
Price / Book2.66

Profitability

Trailing EPS$3.28
Net Income$7.70 billion
Net Margins15.69%
Return on Equity16.03%
Return on Assets8.53%

Miscellaneous

Employees121,597
Outstanding Shares2,317,460,000

Novartis (NYSE:NVS) Frequently Asked Questions

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

How will Novartis' stock buyback program work?

Novartis announced that its board has approved a share buyback plan on Saturday, April 8th 2017, which allows the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase up to 2.9% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's leadership believes its shares are undervalued.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) released its quarterly earnings results on Wednesday, January, 24th. The company reported $1.20 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.16 by $0.04. The firm had revenue of $12.92 billion for the quarter, compared to analysts' expectations of $12.65 billion. Novartis had a net margin of 15.69% and a return on equity of 16.03%. Novartis's revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.14 EPS. View Novartis' Earnings History.

When will Novartis make its next earnings announcement?

Novartis is scheduled to release their next quarterly earnings announcement on Tuesday, April, 24th 2018. View Earnings Estimates for Novartis.

Where is Novartis' stock going? Where will Novartis' stock price be in 2018?

12 brokers have issued twelve-month price targets for Novartis' shares. Their forecasts range from $74.37 to $91.00. On average, they anticipate Novartis' stock price to reach $84.41 in the next year. View Analyst Ratings for Novartis.

Who are some of Novartis' key competitors?

Who are Novartis' key executives?

Novartis' management team includes the folowing people:

  • Vasant Narasimhan M.D., Chief Executive Officer, Member of the Executive Committee
  • Harry Kirsch, Chief Financial Officer, Member of the Executive Committee (Age 53)
  • Felix R. Ehrat Ph.D., Group General Counsel, Member of the Executive Committee (Age 61)
  • Steven Baert, Head of Human Resources, Member of the Executive Committee (Age 44)
  • F. Michael Ball, Chief Executive Officer of Alcon, Member of the Executive Committee (Age 63)
  • James Bradner M.D., President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee (Age 46)
  • Richard D. Francis, Chief Executive Officer of Sandoz, Member of the Executive Committee (Age 50)
  • Paul Hudson, Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee (Age 51)
  • Andre Wyss, President of Novartis Operations, Country President for Switzerland, Member of the Executive Committee (Age 51)
  • Charlotte Pamer-Wieser Ph.D., Corporate Secretary

Who owns Novartis stock?

Novartis' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (0.64%), Parnassus Investments CA (0.41%), Fisher Asset Management LLC (0.29%), BlackRock Inc. (0.17%), Aristotle Capital Management LLC (0.14%) and Mawer Investment Management Ltd. (0.12%). Company insiders that own Novartis stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis.

Who sold Novartis stock? Who is selling Novartis stock?

Novartis' stock was sold by a variety of institutional investors in the last quarter, including The Manufacturers Life Insurance Company , Sterling Capital Management LLC, Franklin Resources Inc., Millennium Management LLC, BB&T Securities LLC, OLD Mission Capital LLC, D.A. Davidson & CO. and BB&T Corp. View Insider Buying and Selling for Novartis.

Who bought Novartis stock? Who is buying Novartis stock?

Novartis' stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Aristotle Capital Management LLC, Senzar Asset Management LLC, Fisher Asset Management LLC, FNY Partners Fund LP, Arrowstreet Capital Limited Partnership and Madison Investment Holdings Inc.. Company insiders that have bought Novartis stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis.

How do I buy Novartis stock?

Shares of Novartis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novartis' stock price today?

One share of Novartis stock can currently be purchased for approximately $85.33.

How big of a company is Novartis?

Novartis has a market capitalization of $223.28 billion and generates $49.11 billion in revenue each year. The company earns $7.70 billion in net income (profit) each year or $3.28 on an earnings per share basis. Novartis employs 121,597 workers across the globe.

How can I contact Novartis?

Novartis' mailing address is Lichtstrasse 35, BASEL, 4056, Switzerland. The company can be reached via phone at +41-61-3241111 or via email at [email protected]


MarketBeat Community Rating for Novartis (NVS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  301 (Vote Outperform)
Underperform Votes:  362 (Vote Underperform)
Total Votes:  663
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Novartis (NYSE:NVS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 1.922.002.082.27
Ratings Breakdown: 4 Sell Rating(s)
5 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
6 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
7 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $84.41$84.41$84.41$84.44
Price Target Upside: 2.85% downside2.85% downside3.26% upside0.30% upside

Novartis (NYSE:NVS) Consensus Price Target History

Price Target History for Novartis (NYSE:NVS)

Novartis (NYSE:NVS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2018JPMorgan Chase & Co.Reiterated RatingNeutralLowView Rating Details
1/2/2018Nord/LBReiterated RatingNeutralMediumView Rating Details
12/6/2017Bank of AmericaDowngradeNeutral -> UnderperformLowView Rating Details
10/25/2017BarclaysDowngradeEqual Weight -> UnderweightN/AView Rating Details
10/23/2017Leerink SwannBoost Price TargetMarket Perform$89.00 -> $91.00N/AView Rating Details
8/9/2017CowenSet Price TargetHold$90.00MediumView Rating Details
7/26/2017Morgan StanleyUpgradeUnderweight -> OverweightLowView Rating Details
7/5/2017Credit Suisse GroupDowngradeNeutral -> Underperform$82.25MediumView Rating Details
3/22/2017Goldman Sachs GroupReiterated RatingNeutralLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageBuy -> BuyLowView Rating Details
3/7/2017Societe GeneraleUpgradeHold -> Buy$73.82 -> $74.37N/AView Rating Details
3/7/2017BNP ParibasDowngradeNeutral -> UnderperformN/AView Rating Details
1/31/2017ArgusUpgradeHold -> BuyN/AView Rating Details
1/17/2017Berenberg BankDowngradeBuy -> HoldN/AView Rating Details
1/9/2017Deutsche BankReiterated RatingNeutralN/AView Rating Details
10/16/2016Jefferies GroupReiterated RatingBuyN/AView Rating Details
10/10/2016Chardan CapitalLower Price TargetBuy$95.00 -> $92.00N/AView Rating Details
5/24/2016CitigroupReiterated RatingNeutralN/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Novartis (NYSE:NVS) Earnings History and Estimates Chart

Earnings by Quarter for Novartis (NYSE:NVS)

Novartis (NYSE NVS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/24/2018        
1/24/2018n/a$1.16$1.20$12.65 billion$12.92 billionViewListenView Earnings Details
10/24/20179/30/2017$1.25$1.29$12.21 billion$12.41 billionViewN/AView Earnings Details
7/18/2017Q2 17$1.16$1.22$12.20 billion$12.24 billionViewN/AView Earnings Details
4/25/20173/31/2017$1.10$1.13$11.59 billion$11.54 billionViewN/AView Earnings Details
1/25/2017Q416$1.12$1.12$12.44 billion$12.32 billionViewN/AView Earnings Details
10/25/2016Q316$1.19$1.23$12.24 billion$12.13 billionViewListenView Earnings Details
7/19/2016Q216$1.18$1.23$12.33 billion$12.47 billionViewListenView Earnings Details
4/21/2016Q116$1.18$1.17$11.90 billion$11.60 billionViewListenView Earnings Details
1/27/2016Q415$1.18$1.14$12.64 billion$12.52 billionViewListenView Earnings Details
10/27/2015Q315$1.31$1.27$12.66 billion$12.30 billionViewListenView Earnings Details
7/21/2015Q215$1.20$1.27$12.45 billion$12.70 billionViewListenView Earnings Details
4/23/2015Q115$1.12$1.33$12.90 million$11.94 billionViewN/AView Earnings Details
1/27/2015Q314$1.13$1.21$14.68 billion$14.63 billionViewN/AView Earnings Details
10/28/2014Q3 2014$1.29$1.28$14.14 billion$14.70 billionViewN/AView Earnings Details
7/17/2014Q214$1.36$1.36$14.83 billion$14.64 billionViewN/AView Earnings Details
4/24/2014Q1 2014$1.33$1.31$14.25 billion$14.02 billionViewN/AView Earnings Details
1/29/2014Q413$1.27$1.20$15.16 billion$15.08 billionViewN/AView Earnings Details
10/22/2013Q313$1.31$1.26$14.28 billion$14.34 billionViewN/AView Earnings Details
7/17/2013Q213$1.29$1.30$14.39 billion$14.50 billionViewN/AView Earnings Details
4/24/2013Q113$1.28$1.32$14.02 million$14.02 billionViewN/AView Earnings Details
1/23/2013Q412$1.19$1.27$14.42 billion$14.80 billionViewN/AView Earnings Details
10/25/2012$1.34$1.34ViewN/AView Earnings Details
7/19/2012$1.33$1.38ViewN/AView Earnings Details
4/24/2012$1.30$1.27ViewN/AView Earnings Details
1/25/2012$1.26$1.23ViewN/AView Earnings Details
10/25/2011$1.45$1.45ViewN/AView Earnings Details
7/19/2011$1.46$1.48ViewN/AView Earnings Details
4/19/2011$1.30$1.41ViewN/AView Earnings Details
1/27/2011$1.25$1.14ViewN/AView Earnings Details
10/21/2010Q3 2010$1.20$1.36ViewN/AView Earnings Details
7/15/2010Q2 2010$1.13$1.20ViewN/AView Earnings Details
1/26/2010Q4 2009$1.16$1.01ViewN/AView Earnings Details
10/22/2009Q3 2009$0.95$0.92ViewN/AView Earnings Details
4/23/2009Q1 2009$0.87$0.87ViewN/AView Earnings Details
1/28/2009Q4 2008$0.79$0.66ViewN/AView Earnings Details
10/20/2008Q3 2008$0.99$0.92ViewN/AView Earnings Details
7/17/2008Q2 2008$0.93$0.99ViewN/AView Earnings Details
1/23/2008Q4 2007$0.67$0.41ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Novartis (NYSE:NVS) Earnings Estimates

2018 EPS Consensus Estimate: $5.50
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$1.31$1.31$1.31
Q2 20181$1.34$1.34$1.34
Q3 20181$1.35$1.35$1.35
Q4 20181$1.50$1.50$1.50
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Novartis (NYSE:NVS) Dividend Information

Most Recent Dividend:3/3/2017
Annual Dividend:$2.30
Dividend Yield:2.70%
Dividend Growth:-0.50% (3 Year Average)
Payout Ratio:70.12% (Trailing 12 Months of Earnings)
42.91% (Based on This Year's Estimates)
39.93% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Novartis (NYSE:NVS)

Novartis (NYSE:NVS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/27/2017Annual$2.333/1/20173/3/20173/3/2017
2/1/2016Annual$2.342/24/20162/26/20162/26/2016
2/4/2014annual$2.723.48%2/27/20143/3/20143/11/2014
2/11/2013annual$2.533.71%2/26/20132/28/20134/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Novartis (NYSE NVS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.01%
Institutional Ownership Percentage: 10.96%
Insider Trades by Quarter for Novartis (NYSE:NVS)
Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Novartis (NYSE NVS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/5/2017Bioventures Ltd NovartisMajor ShareholderBuy266,667$15.00$4,000,005.00View SEC Filing  
5/11/2016Institutes For Biomed NovartisMajor ShareholderBuy277,777$18.00$4,999,986.00View SEC Filing  
2/17/2016Bioventures Ltd NovartisMajor ShareholderBuy375,000$8.00$3,000,000.00View SEC Filing  
9/22/2014Bioventures Ltd NovartisMajor ShareholderBuy325,000$15.00$4,875,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Novartis (NYSE NVS) News Headlines

Source:
DateHeadline
What Investors Can Expect from Vanda Pharmaceuticals in 2018What Investors Can Expect from Vanda Pharmaceuticals in 2018
finance.yahoo.com - February 23 at 6:09 PM
[$$] Greek Parliament Investigates Politicians in Novartis Bribery Probe[$$] Greek Parliament Investigates Politicians in Novartis Bribery Probe
finance.yahoo.com - February 22 at 5:45 PM
Novartis Says Ultibro Breezhaler Significantly Improved Lung, Cardiac Function - NasdaqNovartis Says Ultibro Breezhaler Significantly Improved Lung, Cardiac Function - Nasdaq
www.nasdaq.com - February 22 at 8:07 AM
Undervalued And Attractive: Pick Up Novartis In 2018 - Novartis AG ... - Seeking AlphaUndervalued And Attractive: Pick Up Novartis In 2018 - Novartis AG ... - Seeking Alpha
seekingalpha.com - February 22 at 8:07 AM
[$$] Greek parliament backs Novartis probe[$$] Greek parliament backs Novartis probe
finance.yahoo.com - February 22 at 8:07 AM
Canaccord Slices Regeneron Price Target 32% On Eylea, Dupixent ChallengesCanaccord Slices Regeneron Price Target 32% On Eylea, Dupixent Challenges
finance.yahoo.com - February 21 at 5:35 PM
Novartis Bribery Case in Greece Threatens to Bolster PopulistsNovartis Bribery Case in Greece Threatens to Bolster Populists
finance.yahoo.com - February 21 at 5:35 PM
ACZ885: A Robust Treatment Option for Reducing Cardiovascular Risk?ACZ885: A Robust Treatment Option for Reducing Cardiovascular Risk?
finance.yahoo.com - February 21 at 5:35 PM
Novartis Expects FDA and EMA Approvals for Aimovig in 2018Novartis Expects FDA and EMA Approvals for Aimovig in 2018
finance.yahoo.com - February 21 at 8:07 AM
How Did JNJ’s Vision Care Segment Perform in 4Q17 and 2017?How Did JNJ’s Vision Care Segment Perform in 4Q17 and 2017?
finance.yahoo.com - February 21 at 8:07 AM
Novartis Plans to Expand its Multiple Sclerosis Portfolio in 2018Novartis Plans to Expand its Multiple Sclerosis Portfolio in 2018
finance.yahoo.com - February 21 at 8:07 AM
Novartis Seeks to Acquire Advanced Accelerator ApplicationsNovartis Seeks to Acquire Advanced Accelerator Applications
finance.yahoo.com - February 20 at 5:56 PM
Wedbush: Restorbios Therapy For Aging-Related Diseases Has Best-In-Class PotentialWedbush: Restorbio's Therapy For Aging-Related Diseases Has Best-In-Class Potential
finance.yahoo.com - February 20 at 5:56 PM
Novartis Plans to Launch RTH258 in 2019 to Treat nAMDNovartis Plans to Launch RTH258 in 2019 to Treat nAMD
finance.yahoo.com - February 20 at 5:56 PM
GlaxoSmithKline’s Global Pharmaceuticals Business in 4Q17GlaxoSmithKline’s Global Pharmaceuticals Business in 4Q17
finance.yahoo.com - February 20 at 8:07 AM
Kisqali: Therapy for Advanced Breast Cancer in Premenopausal WomenKisqali: Therapy for Advanced Breast Cancer in Premenopausal Women
finance.yahoo.com - February 20 at 8:07 AM
Today’s Research Reports on Trending Tickers: UnitedHealth Group and NovartisToday’s Research Reports on Trending Tickers: UnitedHealth Group and Novartis
finance.yahoo.com - February 20 at 8:07 AM
MEDIA LINK-Novartis CEO is using data science to revolutionize its drug-development pipeline -WSJMEDIA LINK-Novartis CEO is using data science to revolutionize its drug-development pipeline -WSJ
finance.yahoo.com - February 19 at 5:16 PM
Novartis CEO Steers Drug Maker Back to R&D - Wall Street JournalNovartis CEO Steers Drug Maker Back to R&D - Wall Street Journal
www.wsj.com - February 19 at 8:05 AM
Cosentyx May Change Disease Progression for Ankylosing SpondylitisCosentyx May Change Disease Progression for Ankylosing Spondylitis
finance.yahoo.com - February 19 at 8:05 AM
GlaxoSmithKline’s Business Segments in 4Q17GlaxoSmithKline’s Business Segments in 4Q17
finance.yahoo.com - February 19 at 8:05 AM
Novartis readies to auction U.S. generic pills business - sourcesNovartis readies to auction U.S. generic pills business - sources
finance.yahoo.com - February 16 at 5:25 PM
How an East Bay group is working with the Gates Foundation to stop diarrhea from killing kids - San Francisco Business TimesHow an East Bay group is working with the Gates Foundation to stop diarrhea from killing kids - San Francisco Business Times
www.bizjournals.com - February 16 at 8:08 AM
How Did Pfizer’s Legacy Established Products Segment Perform in 2017?How Did Pfizer’s Legacy Established Products Segment Perform in 2017?
finance.yahoo.com - February 16 at 8:07 AM
3 Tough Questions for Amgen3 Tough Questions for Amgen
finance.yahoo.com - February 15 at 8:28 AM
Novartis AG (NVS) Given Average Recommendation of "Hold" by BrokeragesNovartis AG (NVS) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 14 at 3:28 PM
Dow, S&P 500 and Nasdaq Finish Higher, Posting Third Consecutive Day of GainsDow, S&P 500 and Nasdaq Finish Higher, Posting Third Consecutive Day of Gains
www.thestreet.com - February 14 at 8:31 AM
IIROC Trading Halt - NVSIIROC Trading Halt - NVS
finance.yahoo.com - February 13 at 3:35 PM
Regeneron Could Benefit From 'Lackluster' Data Presented By These RivalsRegeneron Could Benefit From 'Lackluster' Data Presented By These Rivals
finance.yahoo.com - February 13 at 3:35 PM
Greek PM wants politicians investigated in alleged Novartis bribery caseGreek PM wants politicians investigated in alleged Novartis bribery case
finance.yahoo.com - February 12 at 3:36 PM
Novartis promises fast, decisive action if wrongdoing found in GreeceNovartis promises fast, decisive action if wrongdoing found in Greece
finance.yahoo.com - February 12 at 8:19 AM
What’s Expected of Novartis’s Net Profit Margin in 2018?What’s Expected of Novartis’s Net Profit Margin in 2018?
finance.yahoo.com - February 12 at 8:19 AM
How Much Profit Should Novartis Earn By Curing A Childhood Leukemia?How Much Profit Should Novartis Earn By Curing A Childhood Leukemia?
finance.yahoo.com - February 12 at 8:19 AM
Report: Novartis Faces Investigation For Alleged Bribery In GreeceReport: Novartis Faces Investigation For Alleged Bribery In Greece
www.finanznachrichten.de - February 10 at 8:25 AM
[$$] Novartis Faces Investigation For Alleged Bribery In Greece[$$] Novartis Faces Investigation For Alleged Bribery In Greece
finance.yahoo.com - February 10 at 8:25 AM
A Look at Amgen’s Nplate, Vectibix, and Neupogen in 4Q17A Look at Amgen’s Nplate, Vectibix, and Neupogen in 4Q17
finance.yahoo.com - February 9 at 3:44 PM
Ablynx Acquisition Strengthens SNY’s Rare Blood Disorder PlatformAblynx Acquisition Strengthens SNY’s Rare Blood Disorder Platform
finance.yahoo.com - February 9 at 8:25 AM
How Amgen’s Xgeva and Prolia Performed in 4Q17How Amgen’s Xgeva and Prolia Performed in 4Q17
finance.yahoo.com - February 9 at 8:25 AM
Novartis Cosentyx Label Expanded to Include Scalp PsoriasisNovartis' Cosentyx Label Expanded to Include Scalp Psoriasis
finance.yahoo.com - February 8 at 3:34 PM
San Jose startup gets $53M to turn injectable drugs into pillsSan Jose startup gets $53M to turn injectable drugs into pills
www.bizjournals.com - February 8 at 3:34 PM
Patient Advocate Says Novartis $475,000 Breakthrough Should Cost Just $160,000Patient Advocate Says Novartis' $475,000 Breakthrough Should Cost Just $160,000
finance.yahoo.com - February 8 at 3:34 PM
Novartis' Cosentyx Label Expanded to Include Scalp PsoriasisNovartis' Cosentyx Label Expanded to Include Scalp Psoriasis
finance.yahoo.com - February 8 at 3:34 PM
Novartis Gets FDA Approval For Cosentyx Label Update - Quick FactsNovartis Gets FDA Approval For Cosentyx Label Update - Quick Facts
www.nasdaq.com - February 8 at 8:03 AM
How Did Kalydeco Perform in 4Q17 and 2017?How Did Kalydeco Perform in 4Q17 and 2017?
finance.yahoo.com - February 6 at 8:08 AM
Analysts’ Recommendations for Novartis after Its 4Q17 EarningsAnalysts’ Recommendations for Novartis after Its 4Q17 Earnings
finance.yahoo.com - February 6 at 8:08 AM
Greek govt alleges official ties to drug bribery scandalGreek govt alleges official ties to drug bribery scandal
finance.yahoo.com - February 6 at 8:08 AM
Multiple Myeloma May Be Strong Growth Area for GlaxoSmithKlineMultiple Myeloma May Be Strong Growth Area for GlaxoSmithKline
finance.yahoo.com - February 5 at 8:16 AM
How Biogen’s Biosimilars and Interferons Performed in 4Q17How Biogen’s Biosimilars and Interferons Performed in 4Q17
finance.yahoo.com - February 5 at 8:16 AM
Is a Beat in the Cards for Glaxo (GSK) This Earnings Season?Is a Beat in the Cards for Glaxo (GSK) This Earnings Season?
www.zacks.com - February 2 at 8:10 AM
Commentary: How We Can Bring Health Care to the World’s UnderservedCommentary: How We Can Bring Health Care to the World’s Underserved
finance.yahoo.com - February 2 at 8:10 AM

SEC Filings

Novartis (NYSE:NVS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Novartis (NYSE:NVS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Novartis (NYSE NVS) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.